RxDoctor Payments Data

Allan Wohl, DO

Family Medicine · Philadelphia, PANPI 1437199734

Payments from drug & device makers

$8,972in general payments, 2019–2025

Across 516 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$895
  • Lilly USA, LLC$643
  • GSK$629
  • Amarin Pharma, Inc.$508
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$3003%
  • Food & beverage$8,65296%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,972 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,181
Medicare patients
165
Services billed
814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$67,574
JanuviaSitagliptin Phosphate47$52,030
OzempicSemaglutide32$37,194
RybelsusSemaglutide18$24,833
FarxigaDapagliflozin Propanediol21$23,271
XareltoRivaroxaban13$21,099
TradjentaLinagliptin17$17,245
EliquisApixaban13$15,186
Atorvastatin Calcium630$9,315
Losartan Potassium398$5,909
ArexvyRsvpref3 Antigen/As01e/Pf18$5,551
Icosapent Ethyl11$5,143
SymbicortBudesonide/Formoterol Fumarate16$5,072
Rosuvastatin Calcium188$3,634
Levothyroxine Sodium226$3,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$397$84,81983 claims
Novo NordiskOzempic, Rybelsus$895$62,02750 claims
MerckJanuvia$173$52,03047 claims
AstraZenecaFarxiga, Symbicort$1,033$28,34337 claims
Johnson & JohnsonXarelto$35$21,09913 claims
PfizerEliquis$349$15,18613 claims
GSKArexvy$629$5,55118 claims
AbbVieSavella, Synthroid$1,190$4,35544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →